ENDRA Life Sciences Completes Delivery and Installation of its Next Generation Nexus 128+ to Leading Research University in South Korea

Represents ENDRA’s Second Commercial Shipment of its Photoacoustic Imaging System to Research Universities in South Korea

ANN ARBOR, MI / ACCESSWIRE / September 28, 2017 / ENDRA Life Sciences Inc. (“ENDRA”) (NASDAQ: NDRA), a developer of enhanced ultrasound technologies, has delivered and installed its next generation Nexus 128+ preclinical imaging system at Kyungpook National University in Daegu, South Korea.

ENDRA’s preclinical photoacoustic CT scanners are used by leading global research scientists to study disease models. ENDRA’s proprietary hemispherical detector yields full volumetric 3D images of tissue in as little as 3 seconds, without compromised image quality that can result from commonly available slice-based 2D reconstructions. The Nexus 128+ provides up to twice the photoacoustic sensitivity versus ENDRA’s legacy Nexus 128, enabling improved quantitation of preclinical animal models.

“This is ENDRA’s second Nexus installation at a top research university in South Korea and we are excited about the growing global interest in ENDRA’s photoacoustic technology,” said Francois Michelon, ENDRA’s Chief Executive Officer. “Scientists at Kyungpook National University will be using ENDRA’s hemoglobin and probe uptake applications to conduct oncology research with the Nexus 128+ system.

“Looking ahead, we are leveraging our knowledge in photoacoustics to develop a powerful suite of enhancements for clinical ultrasound, that will enable clinicians to visualize human tissues at the point-of-care in ways that are currently only possible with CT or MRI. Utilizing our next generation Thermo-Acoustic Enhanced UltraSound (“TAEUS”) with traditional clinical ultrasound — which is widely available, safe and affordable – will achieve our goal to broaden access to better healthcare,” concluded Michelon.

According to the 2017 Leiden Rankings, Kyungpook National University ranks first among Korean National Universities in the area of biomedical and health science. Kyungpook National University was also ranked 10th Best Global University in South Korea in a 2017 U.S. News and World Report.

About Kyungpook National University

Marking the 71st anniversary since it was established as a flagship comprehensive national university representing Daegu and the Gyeongbuk region, Kyungpook National University (KNU) has been at the forefront in leading national development and nurturing talented youths serving our society. The University has ranked fifth in the QS Asian University Evaluation for the number of papers published and has been selected for seven University Specialization Projects receiving funds of six billion won from the Ministry of Education. KNU was also selected as the execution organization for new medicine development for the Daegu Gyeongbuk Medical Complex, Future Convergence Campus in Daegu Technopolis, and was awarded IEQAS (International Education Quality Assurance System) accreditation by the Korean government. For more information, click here.

About ENDRA Life Sciences Inc.

ENDRA Life Sciences Inc. (“ENDRA”) (NASDAQ: NDRA) is a developer of enhanced ultrasound technologies. ENDRA’s Photo-Acoustic Nexus-128 system is currently used by leading global medical researchers to screen and modify disease models with high image quality and volume scanning speed. ENDRA’s next generation Thermo-Acoustic Enhanced UltraSound (“TAEUS”) will enable clinicians to visualize human tissue composition, function and temperature in ways previously possible only on CT & MRI — at a fraction of the cost, and at the point-of-care. ENDRA’s first TAEUS application will focus on the quantification of fat in the liver, for early detection and monitoring of Non-Alcoholic Fatty Liver Disease, which affects over 1 billion people globally. ENDRA’s goal is to bring new capabilities to ultrasound — thereby broadening access to better healthcare. For more information, please visit www.endrainc.com.

Forward-Looking Statements

All statements in this release that are not based on historical fact are “forward-looking statements.” While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”), which can be found on the SEC’s website at www.sec.gov. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

Company Contact:

David Wells
Chief Financial Officer
(734) 997-0464
investors@endrainc.com
www.endrainc.com

Media & Investor Relations Contact:

MZ North America
Chris Tyson
Managing Director
(949) 491-8235
NDRA@mzgroup.us
www.mzgroup.us

SOURCE: ENDRA Life Sciences Inc.

ReleaseID: 476512